HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

Hosaka, Tetsuya; Suzuki, Fumitaka; Kobayashi, Masahiro; Hirakawa, Miharu; Kawamura, Yusuke; Yatsuji, Hiromi; Sezaki, Hitomi; Akuta, Norio; Suzuki, Yoshiyuki; Saitoh, Satoshi; Arase, Yasuji; Ikeda, Kenji; Kobayashi, Mariko; Kumada, Hiromitsu

doi:10.1111/j.1478-3231.2010.02344.x

Cited by 72 publications

(76 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, serum HBcrAg levels were correlated with CCC DNA levels and frequency of HBcAg (+) hepatocytes in the liver and with liver disease activity [87,89,92,93]. It was also found to predict liver cancer development and recurrence in HBV-infected patients, and was an even better predictor than serum HBV DNA [92,94]. Serum HBcrAg was also found to associate with reactivation of occult hepatitis B following immunosuppressive therapy [91].…”

Section: Potential Applications Of Hbv Particles In Clinical Managmentioning

confidence: 99%

Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application

Liu

2017

Viruses

239

245

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is a para-retrovirus or retroid virus that contains a double-stranded DNA genome and replicates this DNA via reverse transcription of a RNA pregenome. Viral reverse transcription takes place within a capsid upon packaging of the RNA and the viral reverse transcriptase. A major characteristic of HBV replication is the selection of capsids containing the double-stranded DNA, but not those containing the RNA or the single-stranded DNA replication intermediate, for envelopment during virion secretion. The complete HBV virion particles thus contain an outer envelope, studded with viral envelope proteins, that encloses the capsid, which, in turn, encapsidates the double-stranded DNA genome. Furthermore, HBV morphogenesis is characterized by the release of subviral particles that are several orders of magnitude more abundant than the complete virions. One class of subviral particles are the classical surface antigen particles (Australian antigen) that contain only the viral envelope proteins, whereas the more recently discovered genome-free (empty) virions contain both the envelope and capsid but no genome. In addition, recent evidence suggests that low levels of RNA-containing particles may be released, after all. We will summarize what is currently known about how the complete and incomplete HBV particles are assembled. We will discuss briefly the functions of the subviral particles, which remain largely unknown. Finally, we will explore the utility of the subviral particles, particularly, the potential of empty virions and putative RNA virions as diagnostic markers and the potential of empty virons as a vaccine candidate.

show abstract

Section: Potential Applications Of Hbv Particles In Clinical Managmentioning

confidence: 99%

Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application

Liu

2017

Viruses

239

245

View full text Add to dashboard Cite

show abstract

“…Some patients also treated with tenofovir disoproxil fumarate (TDF) which shows incomplete or low responce to ADV therapy [164]. A positive correlation was found between cccDNA and HBcrAg at the incidence of HCC reoccurance, thus cccDNA is a positive haalmark of HBV related HCC reoccurance [165]. It was reported in ScienceDaily that IFN α can cause silencing of cccDNA as well as Lymphtoxin beta receptor (LTbR) agonisation and also can provide novel alternative therapeutic approach for curing CHB infection [166].…”

Section: Role Of Cccdna In Hbv-related Hcc Recurrencementioning

confidence: 99%

HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

Ayub

Ashfaq

Haque

2013

BioMed Research International

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a deadly and emerging disease leading to death in Asian countries. High hepatitis B virus (HBV) load and chronic hepatitis B (CHB) infection increase the risk of developing HCC. HBV is a DNA virus that can integrate DNA into host genome thereby increase the yield of transactivator protein HBxAg that may deregulate many pathways involving in metabolism of cells. Several monogenic and polygenic risk factors are also involved in HCC development. This review summarizes the mechanism involved in HCC development and discusses some promising therapies to make HCC curative.

show abstract

“…However, antiviral therapy was not an independent risk factor [22] . Some studies have demonstrated the suppressive effects of NAs on HCC recurrence [13,21] , whereas other studies did not have indicated that antiviral therapy provided favorable effects [19,20] . The differences between studies may be related to the prevalence of advanced HCC in the subjects and differences in the kinds of NAs administered.…”

Section: Hbv-related Hccmentioning

confidence: 99%

“…Since we reported that lamivudine may potentially prevent HCC recurrence after curative resection of HBV-related HCC [18] , several reports have shown the effects of NAs after treatment of HCC [13,[19][20][21] . Recently, we have evaluated the effects of NAs, primarily of entecavir, on long-term outcomes after curative resection for HCC in patients with a high serum concentration of HBV DNA ( 6 4 log 10 copies/ml) and without portal vein thrombus of the main portal vein as such portal vein thrombus is a strong risk factor for HCC recurrence and may obscure the effects of antiviral therapy [22] .…”

Section: Hbv-related Hccmentioning

confidence: 99%

Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus

Kubo

Takemura²,

Sakata³

et al. 2013

Liver Cancer

View full text Add to dashboard Cite

The outcome after curative resection for hepatocellular carcinoma (HCC) is still unsatisfactory because of the high rate of recurrence of HCC, including intrahepatic metastasis originating from the primary carcinoma and multicentric carcinogenesis after surgery. The rate of recurrence, particularly of multicentric carcinogenesis after surgery, is affected by persistent active hepatitis and hepatic fibrosis caused by chronic hepatitis B or C. In patients with hepatitis B virus (HBV)-related HCC, a high viral load is a strong risk factor for HCC recurrence. Nucleos(t)ide analogues improve the outcome after curative resection for HBV-related HCC. Interferon therapy improves the outcome after curative resection for hepatitis C virus (HCV)-related HCC by decreasing recurrence and preserving or improving liver function when treatment is successful. Low-dose intermittent interferon therapy has also been reported to be effective in suppressing HCC recurrence. New antiviral agents including protease or polymerase inhibitors are expected to be effective because these agents can eradicate HCV in most patients who receive such treatment.

show abstract

HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

Abstract: HBcrAg is a predictor of the post-treatment recurrence of HCC during antiviral therapy. Serum HBcrAg and intrahepatic cccDNA suppression by NAs may be important to prevent HCC recurrence.

Cited by 72 publications

References 37 publications

Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application

Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application

HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus

Contact Info

Product

Resources

About